OVID
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Ovid Therapeutics Inc. (OVID) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Growth (D-). The rating has held at C- for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | D- (1.0) | D- (1.0) | B- (3.1) | C+ (2.6) | C+ (2.6) | C- (2.1) |
| 2026-11-07 | D- (1.0) | D- (0.8) | B (3.2) | B- (2.9) | C+ (2.7) | C- (2.1) |
| 2026-10-31 | D- (1.1) | D- (0.7) | B- (3.1) | B- (3.0) | C+ (2.7) | C- (2.1) |
| 2026-10-24 | D (1.4) | D- (0.8) | B- (3.1) | C+ (2.7) | C+ (2.6) | C- (2.1) |
| 2026-10-17 | D (1.4) | D- (0.8) | B- (3.1) | C+ (2.8) | C+ (2.6) | C- (2.1) |